Alpha 2.0
Login Register
» Authors » Matthew D Hickey

Matthew D Hickey

Explore the profile of Matthew D Hickey including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 44
Citations 462
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Science
Top 10 Co-Authors
Monica Gandhi
Diane V Havlir
Elizabeth Imbert
Elizabeth A Bukusi
Craig R Cohen
Kathryn J Fiorella
Charles R Salmen
James Ayieko
Brian Mattah
Katerina A Christopoulos
Published In
J Acquir Immune Defic Syndr
Clin Infect Dis
AIDS
Clin Orthop Relat Res
PLoS One
Affiliations
Soon will be listed here.
Recent Articles
1.
Identifying preferred program delivery attributes for long-acting injectable cabotegravir-rilpvirine in three U.S. HIV clinics: A discrete choice experiment
Gutierrez Jr J, Montgomery E, Dilworth S, McNulty M, Colasanti J, Johnson M, et al.
J Acquir Immune Defic Syndr . 2025 Mar; PMID: 40079720
Background: Long-acting injectable cabotegravir and rilpivirine (CAB/RPV-LA) may overcome adherence barriers and provide treatment choice among people with HIV (PWH). However, little is known about the factors most likely to...
2.
Aseptic loosening is associated with medial tilting and anterior translational migration of the tibial implant in mechanically aligned total knee arthroplasty
Hickey M, Kaptein B, Anglin C, Masri B, Hodgson A
Clin Biomech (Bristol) . 2025 Mar; 124:106474. PMID: 40054380
Background: Aseptic loosening is a significant cause of implant revision in total knee arthroplasty, and radiostereometric analysis has been used to predict loosening by measuring implant migration over time relative...
3.
Cost-effectiveness of long-acting injectable cabotegravir-rilpivirine as HIV treatment per virally-suppressed persons in a San Francisco clinic: an intermediary outcome analysis
Marseille E, Walker R, Hickey M, Grochowski J, Mayorga-Munoz F, Oskarsson J, et al.
AIDS . 2025 Feb; PMID: 39912762
Background: Long-acting injectable cabotegravir-rilpivirine (CAB/RPV-LA) is a promising treatment alternative for people with HIV (PWH) who face adherence challenges with oral antiretroviral therapy (ART). While its clinical efficacy is well-documented,...
4.
Policy Recommendations to Support Equitable Access to Long-Acting Injectables for Human Immunodeficiency Virus Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association
Marcus J, Weddle A, Kelley C, Agwu A, Montalvo S, Sherman E, et al.
Clin Infect Dis . 2025 Jan; PMID: 39873495
Long-acting injectables (LAIs) for HIV prevention and treatment could dramatically improve health outcomes and health equity for people with HIV and those who could benefit from pre-exposure prophylaxis. Despite widespread...
5.
Cost-effectiveness of leveraging existing HIV primary health systems and community health workers for hypertension screening and treatment in Africa: An individual-based modeling study
Hickey M, Ayieko J, Kabami J, Owaraganise A, Kakande E, Ogachi S, et al.
PLoS Med . 2025 Jan; 22(1):e1004531. PMID: 39854581
Background: Cardiovascular disease (CVD) morbidity and mortality is increasing in Africa, largely due to undiagnosed and untreated hypertension. Approaches that leverage existing primary health systems could improve hypertension treatment and...
6.
Cost-effectiveness of leveraging existing HIV primary health systems and community health workers for hypertension screening and treatment in Africa: an individual-based modelling study
Hickey M, Ayieko J, Kabami J, Owaraganise A, Kakande E, Ogachi S, et al.
medRxiv . 2024 Dec; PMID: 39649589
Background: Cardiovascular disease (CVD) morbidity and mortality is increasing in Africa, largely due to undiagnosed and untreated hypertension. Approaches that leverage existing primary health systems could improve hypertension treatment and...
7.
Use of long-acting injectable cabotegravir/rilpivirine in people with HIV and adherence challenges
Christopoulos K, Hickey M, Rana A
Curr Opin HIV AIDS . 2024 Dec; 20(1):11-18. PMID: 39633536
Purpose Of Review: Recent changes in US Department of Health and Human Services and International AIDS Society USA guidelines now endorse use of long-acting injectable cabotegravir and rilpivirine (LA-CAB/RPV) in...
8.
A Review of Implementation Strategies to Enhance PrEP Delivery for People Experiencing Housing Insecurity: Advancing a Multifaceted High-Touch, Low-Barrier Approach
Velloza J, Mehtani N, Hickey M, Imbert E, Appa A, Riley E
Curr HIV/AIDS Rep . 2024 Nov; 22(1):4. PMID: 39576385
Purpose Of Review: This review summarizes key implementation strategies to advance oral and long-acting PrEP delivery for unstably housed people in the United States. Recent Findings: People experiencing homelessness and...
9.
Learning from the first: a qualitative study of the psychosocial benefits and treatment burdens of long-acting cabotegravir/rilpivirine among early adopters in three U.S. clinics
Christopoulos K, Smith M, Pareek P, Dawdani A, Erguera X, Dance K, et al.
J Int AIDS Soc . 2024 Nov; 27(11):e26394. PMID: 39568168
Introduction: Perspectives on long-acting injectable cabotegravir/rilpivirine (CAB/RPV-LA) from HIV health disparity populations are under-represented in current literature yet crucial to optimize delivery. Methods: Between August 2022 and May 2023, we...
10.
48-week viral suppression rates in people with HIV starting long-acting CAB/RPV with initial viremia
Hickey M, Gistand N, Grochowski J, Mayorga-Munoz F, Imbert E, Szumowski J, et al.
Clin Infect Dis . 2024 Oct; PMID: 39367871
Background: We previously demonstrated at the Ward 86 HIV clinic in San Francisco that long-acting cabotegravir/rilpivirine (LA-CAB/RPV) can rapidly lead to viral suppression (VS) in people with HIV (PWH) with...